Search

Your search keyword '"Gueudry J"' showing total 280 results
Start Over Author "Gueudry J"
280 results on '"Gueudry J"'

1. Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus

Author

Ingen-Housz-Oro, S, Schmidt, V, Ameri, MM, Abe, R, Brassard, A, Mostaghimi, A, Paller, AS, Romano, A, Didona, B, Kaffenberger, BH, Ben Said, B, Thong, BYH, Ramsay, B, Brezinova, E, Milpied, B, Mortz, CG, Chu, CY, Sotozono, C, Gueudry, J, Fortune, DG, Dridi, SM, Tartar, D, Do-Pham, G, Gabison, E, Phillips, EJ, Lewis, F, Salavastru, C, Horvath, B, Dart, J, Setterfield, J, Newman, J, Schulz, JT, Delcampe, A, Brockow, K, Seminario-Vidal, L, Jörg, L, Watson, MP, Gonçalo, M, Lucas, M, Torres, M, Noe, MH, Hama, N, Shear, NH, O’Reilly, P, Wolkenstein, P, Romanelli, P, Dodiuk-Gad, RP, Micheletti, RG, Tiplica, GS, Sheridan, R, Rauz, S, Ahmad, S, Chua, SL, Flynn, TH, Pichler, W, Le, ST, Maverakis, E, Walsh, S, French, LE, and Brüggen, MC

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Dental/Oral and Craniofacial Disease, Humans, Stevens-Johnson Syndrome, Consensus, Skin, Disease Progression, Epidermal necrolysis, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Sequelae, Quality of life, Delphi, Other Medical and Health Sciences, Genetics & Heredity, Genetics, Clinical sciences
Abstract

BackgroundLong-term sequelae are frequent and often disabling after epidermal necrolysis (Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)). However, consensus on the modalities of management of these sequelae is lacking.ObjectivesWe conducted an international multicentric DELPHI exercise to establish a multidisciplinary expert consensus to standardize recommendations regarding management of SJS/TEN sequelae.MethodsParticipants were sent a survey via the online tool "Survey Monkey" consisting of 54 statements organized into 8 topics: general recommendations, professionals involved, skin, oral mucosa and teeth, eyes, genital area, mental health, and allergy workup. Participants evaluated the level of appropriateness of each statement on a scale of 1 (extremely inappropriate) to 9 (extremely appropriate). Results were analyzed according to the RAND/UCLA Appropriateness Method.ResultsFifty-two healthcare professionals participated. After the first round, a consensus was obtained for 100% of 54 initially proposed statements (disagreement index

Published
2023

2. French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis)

Author

Ingen-Housz-Oro, S., Matei, I., Gaillet, A., Gueudry, J., Zaghbib, K., Assier, H., Hua, C., Bensaid, B., Colin, A., Ouedraogo, R., Redlich, J., Courtois, E., Chazelas, K., Sbidian, E., Nakad, L., Bequignon, E., Terkmane, N., Gaultier, F., Schlemmer, F., Do-Pham, G., Barbaud, A., Lebrun-Vignes, B., Hoffmann, C., Mahé, P.-J., Le Floch, R., Bernier, C., Vabres, B., Milpied, B., Delcampe, A., Tétart, F., Tauber, M., Staumont-Sallé, D., Dezoteux, F., Descamps, V., Misery, L., Bursztejn, A.-C., Dereure, O., Amazan, E., Le Bidre, E., Le Pallec, S., Lagier, C., Laroche, A., Ferrat, E., Wolkenstein, P., and de Prost, N.

Published
2024
Full Text
View/download PDF

13. Management of ocular involvement in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: french national audit of practices, literature review, and consensus agreement

Author

Thorel, D., Ingen-Housz-Oro, S., Royer, G., Delcampe, A., Bellon, N., Bodemer, C., Welfringer-Morin, A., Bremond-Gignac, D., Robert, M. P., Tauber, M., Malecaze, F., Dereure, O., Daien, V., Colin, A., Bernier, C., Couret, C., Vabres, B., Tetart, F., Milpied, B., Cornut, T., Ben Said, B., Burillon, C., Cordel, N., Beral, L., de Prost, N., Wolkenstein, P., Muraine, M., and Gueudry, J.

Published
2020
Full Text
View/download PDF

18. Blépharo-conjonctivites sous dupilumab : recommandations du groupe CEDRE. Dermatite atopique, conjonctivites et dupilumab

Author

Doan, S., Arnould, L., Febvay, C., Fournié, P., Gueudry, J., Labalette, P., Ouilhon, C., Tran, T.-H.-C., Vabres, B., Barbarot, S., Bouaziz, J.-D., Du-Thanh, A., Jachiet, M., Seneschal, J., Soria, A., Staumont-Sallé, D., Baudouin, C., Mortemousque, B., Service d'ophtalmologie [Hopital Bichat - Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Service d'Ophtalmologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Ophtalmologie [Hôpital Edouard Herriot - HCL]], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Université Catholique de Lille - Faculté de Médecine, Maïeutique, Sciences de la santé (FMMS), Institut Catholique de Lille (ICL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Centre hospitalier universitaire de Nantes (CHU Nantes), Physiopathologie des Adaptations Nutritionnelles (PhAN), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pathogénèse et contrôle des infections chroniques (PCCI), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Inserm U1035, Biotherapies des Maladies Genetiques et Cancers, Univ Bordeaux, CHU de Bordeaux, Pole de Biologie et Pathologie, Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (CHNO)

Subjects
Dermatite atopique, Conjonctivite, Atopic Dermatitis, Dupilumab, Conjunctivitis, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Dupilumab is a recombinant monoclonal IgG4 type antibody which inhibits IL4 and IL13 signaling. It is indicated in moderate to severe atopic dermatitis (AD) in adults and adolescents over 12 years of age. Its side effects include conjunctivitis and blepharoconjunctivitis, affecting between 4.7% and 28% of patients depending on the study. The incidence of conjunctivitis in patients treated with dupilumab for AD appears to be higher than placebo in clinical studies. This increase was not observed in patients treated with dupilumab for asthma or sinonasal polyposis. The risk factors for conjunctivitis in patients with AD are disease severity, pre-existence of conjunctivitis and low concentrations of dupilumab, but the pathophysiology of this disease is poorly understood. A literature search carried out in April and May 2020 showed an increase in the number of publications on the subject, but there are currently no official joint dermatologist-ophthalmologist recommendations for prevention and management. The objective of this article is to provide an overview of the status of this subject, to address the main questions raised by this type of conjunctivitis and to suggest a course of action for starting and continuing treatment with dupilumab in patients with AD, according to the recommendations of the French Ophthalmologist/Dermatologist group CEDRE.

Published
2022

27. « Hyperpion » de silicone : histoire naturelle et traitement, à propos d’un cas

Author

Pasquier, L., Pereira, E., Gueudry, J., Muraine, M., Lorenzi, U., Hôpital Charles Nicolle [Rouen], Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle (ESCAPE), Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)-Normandie Université (NU)-Université de Reims Champagne-Ardenne (URCA)

Subjects
[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs
Abstract

International audience; « Hyperpion » de silicone : histoire naturelle et traitement, à propos d'un cas Case report of silicone oil ''hyperpion'': Natural history and management

Published
2021

29. Essai randomisé, multicentrique évaluant l’efficacité et la tolérance de l’adalimumab, de l’anakinra et du tocilizumab dans les uvéites réfractaires non infectieuses (RUBI)

Author

Saadoun, D., Ghembaza, A., Sarah, T., Girszyn, N., Philip, B., S. P., Grégory, P., Marc, A., Mathilde, L., Thomas, R., Emmanuel, R., Hie, M., Gaëlle, C.R., Abad, S., Stanescu, D., Toutée, A., Gueudry, J., Bron, A., Kodjikian, L., Vincent, S., Fréderic, C., Titah, C., Emmanuel, H., Asma, M., Trad, S., Terrada, C., Nathalie, M., Domont, F., Anne-Claire, D., Maalouf, G., Vautier, M., Cacoub, P., Kristelle, D., Biard, L., and Bodaghi, B.

Published
2023
Full Text
View/download PDF

32. Supportive care in the acute phase of Stevens–Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi‐based consensus

Author

Brüggen, M.‐C., primary, Le, S.T., additional, Walsh, S., additional, Toussi, A., additional, Prost, N., additional, Ranki, A., additional, Didona, B., additional, Colin, A., additional, Horváth, B., additional, Brezinova, E., additional, Milpied, B., additional, Moss, C., additional, Bodemer, C., additional, Meyersburg, D., additional, Salavastru, C., additional, Tiplica, G.‐S., additional, Howard, E., additional, Bequignon, E., additional, Bouwes Bavinck, J.N., additional, Newman, J., additional, Gueudry, J., additional, Nägeli, M., additional, Zaghbib, K., additional, Pallesen, K., additional, Bygum, A., additional, Joly, P., additional, Wolkenstein, P., additional, Chua, S.‐L., additional, Le Floch, R., additional, Shear, N.H., additional, Chu, C.‐Y., additional, Hama, N., additional, Abe, R., additional, Chung, W.‐H., additional, Shiohara, T., additional, Ardern‐Jones, M., additional, Romanelli, P., additional, Phillips, E.J., additional, Stern, R.S., additional, Cotliar, J., additional, Micheletti, R.G., additional, Brassard, A., additional, Schulz, J.T., additional, Dodiuk‐Gad, R.P., additional, Dominguez, A.R., additional, Paller, A.S., additional, Seminario‐Vidal, L., additional, Mostaghimi, A., additional, Noe, M.H., additional, Worswick, S., additional, Tartar, D., additional, Sheridan, R., additional, Kaffenberger, B.H., additional, Shinkai, K., additional, Maverakis, E., additional, French, L.E., additional, and Ingen‐Housz‐Oro, S., additional

Published
2021
Full Text
View/download PDF

33. Efficacité des anti-TNF alpha dans la prise en charge de l’œdème maculaire cystoïde et des vascularites rétiniennes au cours des uvéites non-infectieuses : étude multicentrique BIOVAS

Author

Maalouf, G., primary, Leclercq, M., additional, Sève, P., additional, Bielefeld, P., additional, Rouviere, B., additional, Girszyn, N., additional, Moulinet, T., additional, Gueudry, J., additional, Sené, T., additional, Sene, D., additional, Cacoub, P., additional, Domont, F., additional, Desbois, A.C., additional, Sarah, T., additional, Bodaghi, B., additional, Biard, L., additional, and Saadoun, D., additional

Published
2020
Full Text
View/download PDF

34. Efficacité des biothérapies dans la prise en charge de l’œdème maculaire cystoïde au cours des uvéites non-infectieuses : étude multicentrique BIOVAS

Author

Leclercq, M., primary, Maalouf, G., additional, Sève, P., additional, Bielefeld, P., additional, Rouviere, B., additional, Girszyn, N., additional, Moulinet, T., additional, Gueudry, J., additional, Sené, T., additional, Sene, D., additional, Cacoub, P., additional, Domont, F., additional, Desbois, A.C., additional, Sarah, T., additional, Bodaghi, B., additional, Biard, L., additional, and Saadoun, D., additional

Published
2020
Full Text
View/download PDF

35. Efficacité du tocilizumab dans la prise en charge de l’œdème maculaire cystoïde et des vascularites rétiniennes au cours des uvéites non-infectieuses : étude multicentrique BIOVAS

Author

Leclercq, M., primary, Maalouf, G., additional, Sève, P., additional, Bielefeld, P., additional, Rouviere, B., additional, Girszyn, N., additional, Moulinet, T., additional, Gueudry, J., additional, Sené, T., additional, Sene, D., additional, Cacoub, P., additional, Domont, F., additional, Desbois, A.C., additional, Sarah, T., additional, Bodaghi, B., additional, Biard, L., additional, and Saadoun, D., additional

Published
2020
Full Text
View/download PDF

36. Efficacité des biothérapies dans la prise en charge des vascularites rétiniennes au cours des uvéites non-infectieuses: étude multicentrique BIOVAS

Author

Maalouf, G., primary, Leclercq, M., additional, Sève, P., additional, Bielefeld, P., additional, Rouviere, B., additional, Sené, T., additional, Girszyn, N., additional, Sene, D., additional, Moulinet, T., additional, Gueudry, J., additional, Cacoub, P., additional, Domont, F., additional, Desbois, A.C., additional, Sarah, T., additional, Bodaghi, B., additional, Biard, L., additional, and Saadoun, D., additional

Published
2020
Full Text
View/download PDF

37. Prise en charge ophtalmologique à la phase aiguë des syndromes de Stevens–Johnson et de Lyell : audit national des pratiques

Author

Thorel, D., primary, Oro, S., additional, Royer, G., additional, Bremond-Gignac, D., additional, Bellon, N., additional, Tauber, M., additional, Malecaze, F., additional, Daien, V., additional, Dereure, O., additional, Bernier, C., additional, Vabres, B., additional, Tetart, F., additional, Milpied, B., additional, Cornut, T., additional, Ben Said, B., additional, Burillon, C., additional, De Prost, N., additional, Wolkenstein, P., additional, Muraine, M., additional, and Gueudry, J., additional

Published
2019
Full Text
View/download PDF

40. Acta Ophthalmol

Author

ROUSSEAU, A., BURREL, S., GUEUDRY, J., DEBACK, C., BORDEREAU, S., MOURIAUX, F., LABALETTE, P., BAZARD, M. C., GABISON, E., BOURCIER, T., SCHWEITZER, Cedric, LABETOULLE, M., Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, LEHA
Published
2018

41. Aciclovir-resistant HSV1 keratitis: a clinical and virological study

Author

Rousseau, A., Burrel, S., Gueudry, J., Deback, C., Bordereau, S., Mouriaux, Frédéric, Labalette, P., Bazard, M. C., Gabison, E., Bourcier, T., Schweitzer, Cedric, Labetoulle, M., and Admin, Oskar

Subjects
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, LEHA
Published
2018

47. Séquelles oculaires invalidantes de la nécrolyse épidermique : facteurs de risque à la phase aiguë et séquelles associées

Author

Hajj, C., primary, Ezzedine, K., additional, Thorel, D., additional, Delcampe, A., additional, Royer, G., additional, Hua, C., additional, Colin, A., additional, de Prost, N., additional, Muraine, M., additional, Chosidow, O., additional, Wolkenstein, P., additional, Gueudry, J., additional, and Oro, S., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results